Business Description
Initiator Pharma AS
ISIN : DK0060775872
Compare
Compare
Traded in other countries / regions
INIT.Sweden IPO Date
2017-03-16Description
Initiator Pharma AS is a research and development company engaged in the pharmaceutical development of drugs to be used for erectile dysfunction, depression, and pain. It Research is focused in the area of monoamine reuptake inhibitors.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.79 | |||||
| Equity-to-Asset | 0.92 | |||||
| Debt-to-Equity | 0.97 | |||||
| Debt-to-EBITDA | -0.95 | |||||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -12.6 | |||||
| 3-Year EPS without NRI Growth Rate | -15 | |||||
| 3-Year FCF Growth Rate | -6.7 | |||||
| 3-Year Book Growth Rate | -21.6 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 25.75 | |||||
| 9-Day RSI | 37.89 | |||||
| 14-Day RSI | 43.01 | |||||
| 6-1 Month Momentum % | -35.18 | |||||
| 12-1 Month Momentum % | -30.35 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 11.8 | |||||
| Quick Ratio | 11.8 | |||||
| Cash Ratio | 8.22 | |||||
| Days Payable | 14.53 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -20.8 | |||||
| Shareholder Yield % | -7.28 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -67 | |||||
| ROA % | -44.51 | |||||
| ROIC % | -219.48 | |||||
| ROC (Joel Greenblatt) % | -484.99 | |||||
| ROCE % | -72.16 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 15.89 | |||||
| Price-to-Tangible-Book | 15.81 | |||||
| EV-to-EBIT | -14.94 | |||||
| EV-to-Forward-EBIT | -42.84 | |||||
| EV-to-EBITDA | -14.94 | |||||
| EV-to-Forward-EBITDA | -42.84 | |||||
| EV-to-Forward-Revenue | 3.31 | |||||
| EV-to-FCF | -21.17 | |||||
| Price-to-Net-Current-Asset-Value | 15.81 | |||||
| Price-to-Net-Cash | 23.45 | |||||
| Earnings Yield (Greenblatt) % | -6.69 | |||||
| FCF Yield % | -4.5 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Initiator Pharma AS Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil kr) | |||
| EPS (TTM) (kr) | -0.318 | ||
| Beta | 0 | ||
| Volatility % | 29.73 | ||
| 14-Day RSI | 43.01 | ||
| 14-Day ATR (kr) | 0.400968 | ||
| 20-Day SMA (kr) | 7.0825 | ||
| 12-1 Month Momentum % | -30.35 | ||
| 52-Week Range (kr) | 6.3 - 11.75 | ||
| Shares Outstanding (Mil) | 56.16 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Initiator Pharma AS Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Initiator Pharma AS Stock Events
| Event | Date | Price(kr) | ||
|---|---|---|---|---|
| No Event Data | ||||
Initiator Pharma AS Frequently Asked Questions
What is Initiator Pharma AS(OSTO:INIT)'s stock price today?
The current price of OSTO:INIT is kr6.80. The 52 week high of OSTO:INIT is kr11.75 and 52 week low is kr6.30.
When is next earnings date of Initiator Pharma AS(OSTO:INIT)?
The next earnings date of Initiator Pharma AS(OSTO:INIT) is 2025-02-28.
Does Initiator Pharma AS(OSTO:INIT) pay dividends? If so, how much?
Initiator Pharma AS(OSTO:INIT) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers